Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study
RNS REACH
PRESS RELEASE
Ergomed Announces Provision of Clinical Research Services for COVID-19
Clinical Study
Guildford, UK – 18 March 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical
industry, today announces the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious
respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). The study is sponsored by the Papa
Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).
Ergomed is providing clinical research services for the study and has been integrally involved in the design and implementation of the study from a clinical and operational perspective.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “COVID-19 represents an unprecedented global healthcare challenge and the rapid evaluation of therapies which could
alter the course of the infection and improve outcomes for patients is vital. Ergomed is proud to be making a contribution to this effort by bringing our proven capabilities and expertise to bear
on this important study.”
The full text of the announcement issued by Papa Giovanni XXIII Hospital and EUSA on 18 March is as follows:
EUSA Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy announce initiation of an observational case-control study of siltuximab in patients with COVID-19 who have developed
serious respiratory complications
Lesen Sie auch
Hemel Hempstead, ENGLAND and Bergamo, ITALY– 18th March 2020 – EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced the initiation of the Papa Giovanni XXIII Hospital sponsored study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). Ergomed plc (LSE: ERGO), a company focused on providing specialized services to the pharmaceutical industry, is providing clinical research services for the study.